论文部分内容阅读
[目的]观察国产紫杉醇联合顺铂的PP方案(Paclitaxel,DDP)在晚期非小细胞肺癌(NSCLC)中的临床近期疗效及毒副反应。[方法]35例晚期NSCLC患者行PP方案化疗,并与同期接受MVP(MMC,VDS,DDP)方案化疗的44例晚期NSCLC比较。[结果]PP组中CR3例,PR13例,NC17例,PD2例。MVP组中,PR13例,NC26例,PD5例,PP组总有效率45.7%,明显高于MVP组(29.5%),但无统计学差异(P>0.05)。毒副反应中PP组白细胞下降和脱发发生率较MVP组高(P<0.05),其余的毒副反应无显著差异(P>0.05)。[结论]国产紫杉醇联合顺铂的治疗方案用于晚期非小细胞肺癌,近期有效率优于MVP方案,毒性反应可耐受,该方案有望在临床治疗晚期NSCLC中得到进一步的推广。
[Objective] To observe the short-term clinical efficacy and side effects of domestic paclitaxel plus cisplatin-based PP regimen (Paclitaxel, DDP) in advanced non-small cell lung cancer (NSCLC). [Method] 35 patients with advanced NSCLC underwent PP regimen chemotherapy and compared with 44 patients with advanced NSCLC receiving MVP (MMC, VDS, DDP) regimen over the same period. [Results] There were 3 cases of CR, 13 cases of PR, 17 cases of NC and 2 cases of PD in PP group. In the MVP group, the total effective rate was 45.7% in PR 13 cases, NC 26 cases, PD 5 cases and PP group, which was significantly higher than that in MVP group (29.5%), but there was no significant difference (P> 0.05). The incidence of leukopenia and alopecia in PP group was higher than that in MVP group (P <0.05). There was no significant difference in other toxic and side effects (P> 0.05). [Conclusion] The domestic paclitaxel combined with cisplatin in advanced non-small cell lung cancer treatment, the recent efficiency is superior to the MVP program, the toxicity can be tolerated, the program is expected to be further extended in the clinical treatment of advanced NSCLC.